StockData
Pulmonx Corp logo

Pulmonx Corp (LUNG) stock

LUNGNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/3040% below fair value
$2.86−0.14 (-4.67%)

Close on Nov 13, 2026Market cap $122.83MP/E –Yield –

Earnings

Pulmonx's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 3, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$22.80M
+6.0% on a year earlier
EPS, Q3 FY2026
-$0.19
-$0.34 a year earlier
Latest guidance
Lowered
Oct 27, 2026 · 4 items

Quarterly results

Revenue and earnings per share from each of Pulmonx's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 3, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Oct 27, 2026after the close$22.80M+6.0%-$0.19Release
Q2 FY2026ended Jun 30, 2026Jul 29, 2026during market hours$22.80M-4.6%-$0.24Release
Q1 FY2026ended Mar 31, 2026Apr 29, 2026during market hours$20.60M-8.4%-$0.33Release
Q4 FY2025ended Dec 31, 2025Mar 4, 2026during market hours$22.60M-5.0%-$0.25Release
Q3 FY2025ended Sep 30, 2025Nov 12, 2025during market hours$21.50M+5.4%-$0.34Release
Q2 FY2025ended Jun 30, 2025Jul 30, 2025during market hours$23.90M+14.9%-$0.38Release
Q1 FY2025ended Mar 31, 2025Apr 30, 2025during market hours$22.50M+19.0%-$0.36Release
Q4 FY2024ended Dec 31, 2024Feb 19, 2025during market hours$23.80M+23.3%-$0.33Release
Q3 FY2024ended Sep 30, 2024Oct 30, 2024during market hours$20.40M+15.3%-$0.36Release
Q2 FY2024ended Jun 30, 2024Jul 31, 2024during market hours$20.80M+20.9%-$0.39Release
Q1 FY2024ended Mar 31, 2024May 1, 2024during market hours$18.90M+30.3%-$0.36Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Pulmonx's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
revenueFY2026$90.00M – $92.00M–NewOct 27, 2026
revenueFY2026$90.00M – $92.00M$90.00M – $92.00MReaffirmedJul 29, 2026
gross marginFY202677%–NewOct 27, 2026
gross marginFY202676%75%RaisedJul 29, 2026
cash, cash equivalents, and marketable securities to decreaseFY2026$22.00M–LoweredOct 27, 2026
cash, cash equivalents, and marketable securities to decreaseFY2026$23.00M$23.00MLoweredApr 29, 2026
total operating expensesFY2026$108.00M – $109.00M–NewOct 27, 2026
total operating expensesFY2026$109.00M – $111.00M$113.00M – $115.00MRaisedJul 29, 2026

Guidance vs results

The last range Pulmonx gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
Q1 FY2022Revenue$9.00M – $10.00M$10.80MAbove range

Guidance history

Every forecast Pulmonx put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 27, 2026gross marginFY202677%New
Oct 27, 2026total operating expensesFY2026$108.00M – $109.00MNew
Oct 27, 2026cash, cash equivalents, and marketable securities to decreaseFY2026$22.00MLowered
Oct 27, 2026revenueFY2026$90.00M – $92.00MNew
Jul 29, 2026gross marginFY202676%Raised
Jul 29, 2026total operating expensesFY2026$109.00M – $111.00MRaised
Jul 29, 2026revenueFY2026$90.00M – $92.00MReaffirmed
Apr 29, 2026gross marginFY202675%Reaffirmed
Apr 29, 2026total operating expensesFY2026$113.00M – $115.00MRaised
Apr 29, 2026cash, cash equivalents, and marketable securities to decreaseFY2026$23.00MLowered
Apr 29, 2026revenueFY2026$90.00M – $92.00MReaffirmed
Mar 4, 2026gross marginFY202675%New
Mar 4, 2026total operating expensesFY2026$113.00M – $115.00MNew
Mar 4, 2026cash, cash equivalents, and marketable securities to decreaseFY2026$23.00MLowered
Mar 4, 2026revenueFY2026$90.00M – $92.00MNew
Nov 12, 2025gross marginFY202573%Lowered
Nov 12, 2025total operating expensesFY2025$125.00M – $126.00MLowered
Nov 12, 2025total revenueFY2025$89.00M – $90.00MLowered
Jul 30, 2025gross marginFY202574%Reaffirmed
Jul 30, 2025total operating expensesFY2025$128.00M – $130.00MLowered

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Pulmonx filed with the SEC as exhibits to Form 8-K or 6-K

  1. Pulmonx Reports Third Quarter 2026 Financial Results
    Results
  2. Pulmonx Reports Second Quarter 2026 Financial Results
    Results
  3. Pulmonx Reports First Quarter 2026 Financial Results
    Results
  4. Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results
    Results
  5. Pulmonx Reports Third Quarter 2025 Financial Results
    Results
  6. Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue;
    Results
  7. Pulmonx Reports Second Quarter 2025 Financial Results
    Results
  8. Pulmonx Reports First Quarter 2025 Financial Results
    Results
  9. Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Results
    Results
  10. Pulmonx Reports Third Quarter 2024 Financial Results
    Results
  11. Pulmonx Reports Second Quarter 2024 Financial Results
    Results
  12. Pulmonx Reports First Quarter 2024 Financial Results
    Results
  13. Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer
    News
  14. Pulmonx Reports Fourth Quarter and Full Year 2023 Financial Results
    Results
  15. Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer
    News

See a number that looks wrong?